clinical-trial-investigator-agreement

name	clinical-trial-investigator-agreement
language	en
description	Drafts U.S. clinical trial Investigator Agreements between sponsors/CROs and principal investigators or institutions for FDA-regulated drug, biologic, or device studies. Enforces 21 CFR Parts 50, 56, 312/812, ICH GCP E6(R2), HIPAA, IRB requirements, FMV/AKS payment compliance, data integrity, publication rights, IP ownership, indemnity, and audit access. Use when drafting investigator agreements, PI agreements, clinical trial site agreements, or sponsor-PI contracts; trigger keywords: investigator agreement, clinical trial agreement, PI agreement, FDA, IND, IDE, IRB, GCP, clinical research agreement, site agreement.
tags	["agreement","drafting","regulatory"]

Clinical Trial Investigator Agreement

Drafts a sponsor–PI/site agreement that operationalizes FDA, IRB, and GCP obligations for a specific clinical trial.

Prerequisites

1. Protocol number, title, version date, phase, endpoints, enrollment target.
2. Investigator's brochure or device manual; investigational product handling requirements.
3. Sponsor identity, CRO involvement, contracting structure (institution, PI, or both).
4. Site legal name, state law, institutional policies, and any required template language.
5. PI credentials, sub-investigators, study team roles.
6. Budget and payment model (per subject, per visit, milestones); invoicing rules.
7. IRB details, consent/assent forms, recruitment materials, vulnerable population plan.
8. Data ownership, publication expectations, IP posture, sample handling.
9. Insurance positions and indemnity constraints (public entities, academic limits).

Output Structure / Process

1. Intake — targeted questions; confirm drug/biologic (21 CFR 312) vs device (21 CFR 812) track.
2. Draft — follow the section order below, incorporating site-specific policies.
3. Exhibits — attach and incorporate by reference.
4. Verify — run compliance checks using the tables and checklist below.

Regulatory Baseline

Topic	Authority
Informed consent	21 CFR Part 50; LAR, assent where required
IRB	21 CFR Part 56; 45 CFR 46 when institution requires
Drugs/Biologics	21 CFR Part 312; IND obligations flow down
Devices	21 CFR Part 812; IDE obligations flow down
GCP	ICH GCP E6(R2)
Financial disclosure	21 CFR Part 54
Privacy	HIPAA and state privacy laws
Vulnerable populations	45 CFR 46 Subparts B, C, D

Agreement Sections

Section	Must Include
Parties and Definitions	Sponsor, institution, PI; define Study, Protocol, Investigational Product, SAE, Confidential Information
Study Description	Protocol incorporated by reference; scope; single vs multi-center
Investigator Responsibilities	Conduct per protocol; no deviations except to eliminate immediate hazard; amendment approval workflow
IRB and Approvals	No study activities before written IRB approval; continuing review; submissions shared with sponsor
Informed Consent	Current IRB-approved forms; qualified designee; no coercion; LAR and assent as applicable
Study Personnel	Delegation of authority log; training documentation; PI retains ultimate responsibility
Investigational Product	Receipt only from sponsor; storage conditions; accountability logs; no off-protocol use; return/destroy per sponsor
Safety Reporting	AE/SAE definitions; sponsor reporting timelines; IRB reporting for unanticipated problems
Data Integrity	ALCOA+; source data verification; correction rules; EDC audit trail
Records and Retention	Essential documents per ICH GCP § 8; retention per 21 CFR 312.62(c) / 812.140(d), or longer per law/policy
Monitoring and Access	Reasonable advance notice; direct source access; HIPAA minimum necessary; corrective actions
Regulatory Inspections	Notify sponsor within 24 hours; provide FDA 483 or correspondence within 5 business days
Confidentiality	Scope; permitted disclosures to IRB/regulators; term and return/destruction
Data and IP Ownership	Sponsor owns study data and results; invention assignment; sample ownership with institutional carve-outs
Publications	Sponsor review window; patent delay; multicenter coordination; ICMJE authorship standards
Compensation and Budget	FMV/AKS compliance; invoicing; screen fail and early withdrawal rules; startup/closeout costs
Financial Disclosure/COI	21 CFR Part 54 disclosures; update obligations; conflict management
Indemnification	Sponsor product liability indemnity; carve-outs for PI/site negligence or noncompliance
Insurance

Exhibits

• Protocol and amendments
• Budget and payment schedule
• Study team roster and qualifications
• Financial disclosure forms
• Informed consent/assent forms
• Institutional policies incorporated by reference
• Publication policy (if separate)

Default Timelines

Adjust to protocol/IRB policy.

Event	Default
Sponsor notification of SAE	Within 24 hours of awareness
IRB submission of unanticipated problems	Per IRB policy, prompt reporting
Publication review by sponsor	45–60 days before submission
Patent delay after review	Up to 60–90 days

Final Checks

• Parties and governing law match site and sponsor
• All regulatory citations align with drug/biologic vs device track
• Consent and privacy requirements align with site policy
• Payment terms are FMV and AKS compliant
• Indemnity/insurance reflect institutional limits
• Every unverified citation marked [VERIFY]

Troubleshooting

Issue	Resolution
Unclear whether drug or device track applies	Confirm IND (21 CFR 312) vs IDE (21 CFR 812) with sponsor; combination products follow primary mode of action
Institution requires its own template	Merge sponsor terms into institutional template; flag conflicts for negotiation
Public entity cannot indemnify	Carve out sovereign immunity; shift to insurance-only model with higher certificate minimums
PI holds multiple roles (e.g., also sponsor-investigator)	Apply 21 CFR 312.50–312.70 sponsor obligations in addition to investigator duties
Budget exceeds FMV benchmarks	Document FMV analysis methodology; adjust per AAMC/PhRMA guidelines to avoid AKS risk

Guidelines

• Apply the most stringent requirement among federal law, state law, and institutional policy.
• No study activity before IRB approval and full execution if required by the institution.
• Keep confidentiality and publication clauses consistent with multi-center coordination.
• Preserve a clear audit trail for data corrections and monitoring access.
• Flag any unclear regulatory citation with [VERIFY].

---